{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-043761","form_type":"8-K","ticker":"FRMM","cik":"0001690080","company_name":"FORUM MARKETS Inc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.620523+00:00","generated_at":"2026-06-01T23:19:43.175354+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"180 Life Sciences receives Nasdaq delisting notice after failing to meet equity requirement","bullets":["Company failed to regain compliance with Nasdaq's minimum $2.5M stockholders' equity by May 13, 2024 deadline.","Received delist determination letter on May 14, 2024; trading suspension scheduled for May 23, 2024 unless appeal.","Intends to request a hearing before Nasdaq Hearings Panel, which would stay delisting pending process.","Also notified of non-compliance with audit committee composition (need three independent directors); cure period until May 2025.","Common stock (ATNF) and warrants (ATNFW) will continue trading on Nasdaq pending hearing outcome."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-043761","json":"https://secwatch.observer/filing/0001213900-24-043761.json","markdown":"https://secwatch.observer/filing/0001213900-24-043761.md","text":"https://secwatch.observer/filing/0001213900-24-043761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690080/000121390024043761/0001213900-24-043761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690080/000121390024043761/ea0206133-8k_180lifesci.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:19:43.175354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"628df9c51d05112774e74ac926ebd4354e889210","claim":"FORUM MARKETS Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"November 15, 2023, the Listing Qualifications department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notified 180 Life Sciences Corp. (the “ Company ”, “ we ” and “ us ”) that we did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b) (the “ Rule ”). Nasdaq provided the Company until January 2, 2024 to submit to Nasdaq a plan to regain compliance. We submitted the plan to regain compliance in a timely manner, and on January 11, 2024, Nasdaq advised the Company that it has determined to grant the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690080/000121390024043761/0001213900-24-043761-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}